Pneumology: Anti-IgE antibodies in the treatment of asthma;Pneumologie: Anticorps anti-IgE dans le traitement de l'asthme

Revue Medicale Suisse

Volumn 3, Issue 93, 2007, Pages 56-59

  Leuenberger, Philippe ^a   Sauty, Alain ^a   Rochat, Thierry ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

ALLERGIC ASTHMA; ANAPHYLAXIS; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; INJECTION SITE REACTION; LUNG FUNCTION TEST; PRICK TEST; REVIEW; THROMBOCYTOPENIA;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN E;

EID: 33846648461     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Tough SC, Hessel PA, Ruff M, et al. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657-65.
2. Turner MO, Noertjojo K, Vedal S, et al. Risk factors for near-fatal asthma. A case control study in hospitalised patients with asthma. Am J Respir Crit Care Med 1998;157:1804-9.
3. Nizankowska E, Soja J, Pinis G, et al. Treatment of steroid-dependent bronchial asthma with cyclosporine. Eur Respir J 1995;8:1091-9.
4. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;2:CD002985.
5. Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322-6.
6. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;354:2689-95.
7. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-93.
8. Fahy JV, Fleming E, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
9. Soler M, Matz J, Twnley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61.
10. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90.
11. Holgate S, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-8.
12. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin IgE antibody (omalizumab). Pediatrics 2001;108:E36.
13. Humbert M, Beasley R, Ayres J, et al. Benefits of omaHzumab as add-on therapy in patients with asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment). Allergy 2005;60:309-16.
14. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17.
15. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125:1378-86.
16. Avila PC. Does anti-IgE therapy helps in asthma? Efficacy and controversies. Annu Rev Med 2007;58 (Epub ahead of print).